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ABSTRACT 
A fixed-dose combination (FDC) drug is a one that includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage 
form, which is manufactured and distributed in fixed doses [1]. It increases patient compliance by reducing the no. of medications that a patient 
has to take especially for geriatric and pediatric patients. Orally disintegrating tablets (ODTs) are solid dosage forms containing a medicinal 
substance or active ingredient that rapidly disintegrates upon contact with saliva, typically within 30 s, eliminating the need for swallowing. It 
also increases patient compliance by reducing the swallowing problems faced by the patients especially for geriatric and pediatric patients. This 
review is about combining the techniques of both FDC and ODT formulations which promises to have a wide range of advantages to pediatric and 
geriatric populations, institutionalized and psychiatric patients, those suffering from nausea and vomiting, and individuals with lack of access to 
water. In spite of these advantages rarely do we find FDC-ODT products in our commercial market, this review aims at analyzing all the aspects 
of FDC and ODT formulations thereby forming the foundation for further studies. 
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Initially, fixed-dose combination drug products were 
developed to target a single disease (such as 
with antiretroviral FDCs used against AIDS). However, FDCs 
may also target multiple diseases/conditions, such as Caduet 
(atorvastatin/amlodipine) or Exforge 
(amlodipine/valsartan). In cases of FDCs targeting multiple 
conditions, such conditions might often be related—in order 
to increase the number of prospective patients who might be 
likely to utilize a given FDC product. This is because each 
FDC product is mass-produced, and thus typically requires 
having a critical mass of potentially applicable patients in 
order to justify its manufacture, distribution, stocking, etc.2 It 
is therefore safe to say that the FDCs have more advantages 
when there is an identifiable patient population for whom 
treatment with a particular combination of actives in a fixed 
ratio of doses has been shown to be safe and effective, and 
when all of the actives contribute to the overall therapeutic 
effect. In addition there can be real clinical benefits in the 
form of increased efficacy and/or a reduced incidence of 
adverse effects, but such claims should be supported by 
evidence. 
Definition: The Food and Drug Administration, USA defines 
a combination product as ‘a product composed of any 
combination of a drug and a device or a biological product 
and a device or a drug and a biological product or a drug, 
device, and a biological product’ 3 
Combination Rule: The primary guiding principle for the 
approval of FDC products is the combination rule as 
described in FDA’s guidance for development of FDC and co-
packaged drug products as well as in 21CFR 300.50, which 
describes FDA’s policy on the approval of FDC products for 
humans. This rule states that “Two or more drugs may be 
combined in a single dosage form when each component 
makes a contribution to the claimed effects and the dosage of 
each component (amount, frequency, duration) is such that 
the combination is safe and effective for a significant patient 
population requiring such concurrent therapy as defined in 
the labeling for the drug.” 4 
Synonyms: Combopill, Polypill. 2 
ADVANTAGES 
1. Offers improved compliance and convenience to 
patients and prescribers. 
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2. The cost of an FDC finished pharmaceutical product 
(FDC-FPP) may be less than that of separate products 
given concurrently. 
3. Improves patient adherence and reduces the 
development of resistance in the case of antimicrobials. 
4. Simplifies the logistics of procurement and distribution. 
DISADVANTAGES 
1. FDCs are less likely to be useful under the following 
circumstances. 
a) Either the doses of the components, and/or the ratio of 
doses, typically differ from patient to patient. 
b) Patients are likely to be taking different doses at 
different stages of treatment (for example initial 
treatment compared with long-term treatment).  
c) Dose adjustment is necessary in special populations, 
such as in people with renal or hepatic impairment. 
2. The resulting FDC product may be so large that patients 
find it difficult to swallow. 
3. Dosage alteration of one drug is not possible without 
alteration of the other drug. 5 
4. Differing pharmacokinetics of constituent drugs pose 
the problem of frequency of administration of the 
formulation. 5 
5. By simple logic there are increased chances of adverse 
drug effects and drug interactions compared with both 
drugs given individually. 5 
6.  If an adverse drug reaction occurs from using an FDC, it 
may be difficult to identify the active ingredient 
responsible for causing the reaction. 2 
For a successful development of a new FDC product there 
must be a balance between these advantages and 
disadvantages. A proper way for going about this is listing 
and discussing them based on scientific and medical 
principle. 
 PROPERTIES ESSENTIAL FOR AN FDC PRODUCT 
1. There must be a medical rationale in combining two or 
more active pharmaceutical ingredient. For example, 
a) For antimicrobials, the combination should result in a 
reduced incidence of resistance.  
b) In the case of some antiviral drugs, one drug should act 
as a booster for another. 
2. The component actives must have compatible 
pharmacokinetics and/or pharmacodynamics (i.e.) it 
should remain unchanged when combined into a FDC 
product. 
3. The FDC product must be bio-equivalent to the 
individual products of similar strengths. 
4. The drugs in the combination should act by different 
mechanisms. 5 
5. It must provide better reliability and patient adherence 
than all of the components as loose combinations of 
single entity products 
6. There must be an identifiable patient group for which 
this combination of actives and doses is suitable 
therapy. The larger the patient group in question, the 
more significant is this factor. 
7. The incidence of adverse reactions in response to 
treatment with the combination must be lower than in 
that response to any of the component actives given 
alone, for example as a result of a lower dose of one 
component or a protective effect of one component, and 
particularly when the adverse reactions are serious. The 
combination should not have supra-additive toxicity of 
the ingredients. 5 
8. The active pharmaceutical ingredients in the 
combination must be chemically and physic-chemically 
compatible, or special formulation techniques must 
have been used that adequately addresses any 
incompatibility. 
9. The cost of the combination as compared with the cost 
of individual components must be taken into account.  
However, issues of cost and procurement alone are not 
sufficient reason to approve an FDC if it has not been 
justified by appropriate data and on scientific and medical 
principles.  
ADDRESSING THE IRRATIONALITY PROBLEMS 
ASSOCIATED WITH FDC PRODUCTS 
It is no secret that our health system today has fallen prey to 
a number of irrational FDC products. Many products are 
being manufactured and marketed without any medical 
rationale behind it. This is a major concern because these 
products expose patients to unnecessary risk of adverse 
drug reactions. Some of the products that were proven to be 
irrational and the reasons for their irrationality are given 
below. 
 
Table 1: Drug combinations and their irrationality 7: 
S.N. Drug combinations Irrationality 
1. Norfloxacin + 
Metronidazole; Norfloxacin 
+ Tinidazole; Norfloxacin + 
Tinidazole + Loperamide 
Though claimed to be broad spectrum, combining (antiamoebic) with fluoroquinolone 
(antibacterial) is irrational because patient suffers only from one type of diarrhoea. Using 
this combination adds to cost, adverse effects and may encourage resistance. 
2. Nimesulide + Diclofenac; 
Nimesulide + Dicyclomine + 
Simethicone; Nimesulide + 
Paracetamol; 
Nimesulide a controversial drug, has been banned in many countries. It is a sorry state of 
affairs that its combinations are readily available over the counter. Combining two 
NSAIDs may increase the side effects of both the NSAIDs. There is little documentary 
evidence that a preparation containing more than one analgesic is more effective than a 
single ingredient preparation. 
3. Amoxycillin + Cloxacillin Amoxycillin is inactive against staphylococcus, as most strains produce ß-lactamase and 
cloxacillin is not so active against streptococci. For any given infection, one of the 
components is useless but adds to cost and adverse effect. Since amount of each drug is 
halved, efficacy is reduced and chances of selecting resistant strains is increased. 
4. Domperidone + 
Rabeprazole; Domperidone 
+ Esomeprazole 
Increased incidence of rhabdomyolysis. 
5. Enalapril + Losartan Combining two drugs affecting the same pathway is irrational; it doesn’t add to efficacy. 
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In an attempt to stop the irrational use of FDCs, the Union 
Health Ministry banned the manufacture, sale or distribution 
of 328 varieties of FDC drugs for human consumption. Thus 
it is important that there must be a proper risk-benefit 
assessment carried out before the manufacture of FDC 
products. The risk must not outweigh the benefits of FDCs. 
FORMULATIONS IN WHICH FDC PRODCUTS ARE 
AVAILABLE 
 Tablet 
a) Film coated tablet 
b) Bilayered tablet 
c) Trilayered tablet 
d) Tablet in tablet 
e) Coated beads in tablet 
f) Chewable tablet 
g) Dispersible tablet 
 Capsules 
a) Capsule in capsule 
b) Beads and powder in capsule 
c) Coated beads in capsule 
d) Coated powder in capsule 
 Topical preparations and Transmucosal preparations 
 Injectables and Inhalations 
 Syrup and Suspension 
 Ear and eye drops 
 
 
Table 2: List of a few examples of the available FDC products (US-FDA approved) 8. 
Active ingredient Proprietary name Category Strenght 
Sulfamethoxazole, Trimethoprim Sulfatrim –SS  Anti-infective Agents -  
Antibiotics 
800mg, 160mg (or) 
400mg , 80mg 
Reserpine, Trichlormethiazide Metatensin #2 Antiadrenergics,Diuretics 0.1mg, 2mg 
Pyrimethamine, Sulfadoxine Fansidar Antimalarials 25mg, 500mg 
Oxytetracycline hydrochloride, 
Polymyxin B Sulfate 
Terramycin-Polymyxin Antibiotics EQ 100mg Base, 1,00,000 
Units 
Naloxone Hydrochlorise, Pentazocaine 
hydrochloride 




Avandamet Anti-diabetics 500mg, EQ 1mg Base (or) 
1g EQ 2mg Base 
Magnesium Hydroxide, Omeprazole, 
Sodium Bicarbonate 
Zegerid Laxative, Anti-ulcer, Antacid 700mg, 20mg, 600mg (or) 
700mg, 40mg, 600mg 
 
Applications 
1. FDCs are particularly useful in the management of 
HIV/AIDS, malaria and tuberculosis, which are 
considered to be the foremost infectious disease threats 
in the world today. 
Specific Evaluation Tests  
1. Bioequivalence Testing: In general, the bioequivalence 
guidelines for FDCs are fundamentally similar to those 
for products containing a single API. In other words, the 
rate and extent of absorption of each active from FDC 
should not be significantly different, respectively, from 
the rate and extent of each active from individual mono-
products. In spite of subtle differences in BE criteria 
among various agencies, the common critical 
pharmacokinetic parameters are AUC0 − t, AUC0 − ∞, 
and Cmax in studies to determine bioequivalence after a 
single dose. For these parameters, the 90% confidence 
interval for the ratio of the FDC (test) and individual 
mono-products (references) should be contained within 
the acceptance interval of 80.00–125.00% . 9, 10 
ODTs 
Orally disintegrating tablets (ODTs) are solid dosage forms 
containing a medicinal substance or active ingredient that 
rapidly disintegrates upon contact with saliva, typically 
within 30 s, eliminating the need for swallowing. ODTs are a 
new generation of formulations which combine the 
advantages of both liquid and conventional tablet 
formulations, and at the same time, offer added advantages 
over both the traditional dosage forms. They provide the 
convenience of a tablet formulation and also allow the ease 
of swallowing provided by a liquid formulation. Thus it 
greatly improves compliance for patients suffering from 
dysphagia (difficulty in swallowing), a condition estimated to 
affect as much as 50% of the population. Dysphagia is 
particularly prevalent in pediatric and geriatric populations, 
institutionalized and psychiatric patients, those suffering 
from nausea and vomiting, and individuals with lack of 
access to water. 12-15 
Initially ODT products entered the market in the 1980s, after 
which its demand has only grown steadily. Oral route has 
always been the most preferred route of administration to 
patients for decades because of the several advantages and 
high patient compliance. Among the oral route tablets and 
hard gelatin capsules constitute the major portion.  However, 
many patient groups such as the elderly, children, and 
patients who are mentally retarded, uncooperative, 
nauseated, or on reduced liquid-intake/diets have difficulties 
swallowing these dosage forms. Those who are traveling or 
have little access to water are similarly affected. ODTs are 
considered superior dosage forms than tablets and capsules 
because it overcomes several of these disadvantages by 
disintegrating rapidly in saliva, usually in a matter of 
seconds, without the need to take it water and thus avoiding 
swallowing difficulties.   Thus many research scholars were 
encouraged and interested to conduct studies to find out 
different possibilities and approaches in the generation of 
ODTs. 
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When put in the mouth, these dosage forms disintegrate 
instantly to release the drug, which dissolves or disperses in 
the saliva. 16 Thereafter, the drug may get absorbed from the 
pharynx and esophagus or from other sections of GIT as the 
saliva travels down. In such cases, bioavailability is 
significantly greater than that observed from conventional 
tablet dosage form.17 
ODTs are distinguished from conventional sublingual tablets, 
buccal tablets, and lozenges, which require more than a 
minute to dissolve in oral cavity. 18 
 
Figure 1 Absorption of drug from an intact tablet. 
 
Definition: The US Food and Drug Administration Center for 
Drug Evaluation and Research (CDER) defines, in the ‘Orange 
Book’, an ODT as “a solid dosage form containing medicinal 
substances, which disintegrates rapidly, usually within a 
matter of seconds, when placed upon the tongue”20. The 
significance of these dosage forms is highlighted by the 
adoption of the term, “Orodispersible Tablet”, by the 
European Pharmacopoeia which describes it as a tablet that 
can be placed in oral cavity where it disperses rapidly before 
swallowing. 21 
Synonyms: Fast melts, Quick melts, Fast disintegrating, 
Orodispersible systems, orodisperse, mouth-dissolving, 
quick-dissolve, freeze-dried wafers, rapimelts, melt-in-
mouth tablets and rapid dissolving table.22-26 
Advantages: 17, 18 
1. Patients with difficultly in chewing and swallowing 
(dysphagia) can use these ODTs tablets easily. Thus the 
risk of chocking or suffocation during oral 
administration of conventional formulations due to 
physical obstruction is avoided 27  
2. Since there is no water requirement for swallowing 
purpose it is suitable during traveling, where water may 
not be available 17 
3. Drug dissolution and absorption as well as onset of 
clinical effect and drug bioavailability may be 
significantly greater than those observed from 
conventional dosage forms 17 
4. ODTs can be used easily in children who have lost their 
primary teeth but do not have full use of their 
permanent teeth 18 
5. Avoids first pass metabolism as it undergoes pre-gastric 
absorption in buccal, pharyngeal and gastric regions. 
6. Provides pleasant feeling in the mouth 17  
7. The characteristics of ODTs can simply be adjusted to 
required levels by reducing or increasing the 
compression force for each formulation, and/or by only 
adding formulation aids 28 
8. A simple direct compression technique is conveniently 
enough for the preparation of oro-dispersible tablets 
when suitable excipients are used. Thus conventional 
manufacturing equipment is sufficient 18 
9. Good stability, accurate dosing and easy handling by 
patients 17 
10. Good mechanical properties such as increased hardness 
and decreased friability 18 
11. ODT opened new business opportunity like product 
differentiation, product promotion, patent extension 
and  life cycle management 17 
12. No specific packaging required can be packaged in push 
through blisters 17 
13. They simply vanish when placed in the mouth, so cannot 
be hidden in mouth by psychotic patients 17 
 
Figure 2 Advantages of ODT 
 
Disadvantages: 17, 18 
1. Permeability barrier of the oral mucosa is a 
disadvantage. 
2. Oral absorption surface area is relatively small. 
3. Taste masking may be necessary for bitter tasting drugs. 
4. Mastication and speech may affect oral absorption of 
ODT. 
5. Decreased volume of saliva may slow the rate of 
disintegration/dissolution and decrease the 
bioavailability of the product. Therefore patients with 
diseases that reduce salivary secretion will not be able 
to take this formulation. 
6. ODT formulations are more susceptible to degradation 
via temperature and humidity. 
7. ODT is hygroscopic in nature so must be keep in dry 
place. 
8. The granules of ODTs sometimes show fragile, 
effervescence property. 
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PROPERTIES ESSENTIAL FOR AN ODT PRODUCT: 
1. The tablet must possess a disintegration time below 30 
s 29 
2. It should have sufficient strength to withstand the rigors 
of the manufacturing process and post-manufacturing 
handling 30 
3. It should have high drug loading 30 
4. It should have a pleasant mouth feel 30 
5. It should be insensitive to environmental conditions 
such as humidity and temperature 30 
6. It should be adaptable and amenable to existing 
processing and packaging machineries 30 
7. For lyophilized dosage forms, the drug dose must be 
lower than 400 mg for insoluble drugs and less than 60 
mg for soluble drugs 30 
8. It should leave negligible or no residue in the mouth 
after oral administration. 
 
MECHANISM OF ODT DISINTEGRATION 
 
Figure 3: Mechanism of ODT disintegration
 
Figure 4 Mechanism of ODT disintegration 
 
NEED FOR ODT: 
1. Patient factors - For patients, who find it inconvenient 
to swallow traditional tablets and capsules like pediatric 
patients, geriatric patients, patients with fear of choking, 
patients with persistent nausea, schizophrenic patients, 
and patients with no access to water 31-34 
2. Effectiveness factors – For drugs that undergo a great 
deal of hepatic metabolism. Furthermore, safety profiles 
may be improved for drugs that produce significant 
amounts of toxic metabolites mediated by first-pass 
liver metabolism and gastric metabolism, and for drugs 
that have a substantial fraction of absorption in the oral 
cavity and pregastric segments of GIT 35,36 
3. Manufacturing and marketing factors - A new dosage 
form allows a manufacturer to extend market 
exclusivity, unique product differentiation, value-added 
product line extension, and extend patent protection, 
while offering its patient population a more convenient 
dosage form. This leads to increased revenue, while also 
targeting underserved and under-treated patient 
populations 37 
EXCIPIENTS USED IN THE FORMULATION OF ODT: 
The mixture of excipients used in the formulation of ODT 
may comprise of at least one disintegrating agent, a soluble 
diluents, a lubricant and optionally a swelling agent, a 
permeabilizing agent, sweeteners, flavoring agents and color 
19 
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The typical property of ODTs can be attained by addition of 
different varieties of excipients. But the number of 
fillers/binders/disintegrant which can be used for ODT 
formulations is limited because these bulk excipients have to 
fulfill special requirements, such as being soluble in water, 
pleasant taste, mouth feel, sweetness, and rapid 
dispersibility. New combinations of existing excipients are an 
interesting option for improving excipient functionality. 
Mannitol is extensively used as diluent but now modified 
mannitol is available which give extensive flow, compression 
and rapid dispersibility to the tablet e.g. like Orocell, 
Mannogem EZ, and Pearlitol SD 200 19 
Most recently functional excipients also called as co 
processed excipients are available in market such as 
Ludiflash, Pharmburst, and F- MELT 19 
 
Table 4: Composition and characteristics of excipients 19 
Excipients Composition and characteristics 
Pharmburst  Coprocessed blends of Mannitol, Starch, Crosspovidone, Cross Carmellose Sodium, Collidal 
Silica and Silica 
Ludiflash Coprocessed blends of 90% Mannitol, 5% Kollidon CL-SF (Crosspovidone), 5% Kollicoat SR 
30D (Polyvinyl Acetate) 
F-MELT Coprocessed blends of Mannitol, Xylitol, Calcium Sulphate, Crosspovidone, and Mangesium 
Alumino metasillicate. 
Modified chitosan with 
silicon dioxide 
Coprecipitation of Chitosan and Silica. 
Orocell 200 & Orocell 400 Orocell 200 with 90% Mannitol (<315μm). 
Orocell 400 with 90% Mannitol (<500μm). 
Advantose Spray dried disaccharide carbohydrate maltose powder 
Polacrilin Potassium Potassium salt of a cross linked polymer derived from methacrylic acid and divinyl benzene. 
 
Applications: 
1. ODT products have been developed for numerous 
indications ranging from migraines (for which rapid 
onset of action is important) to mental illness (for which 
patient compliance is important for treating chronic 
indications such as depression and schizophrenia. 
Challenges: 
1. Proper selection of excipients for a short 
disintegration time (less than 3 min – according to the 
European Pharmacopoeia 6.0, or less than 30 s – 
recommended by the FDA) 38 
2. Palatability: As most drugs are unpalatable, the 
medicaments given as ODTs must be appropriately 
taste-masked. It is also challenging to the formulators to 
select the method to be adopted for taste-masking 39, 40 
3. Mechanical strength: In order to allow ODTs to 
disintegrate in the oral cavity, they are made of either 
very porous or soft-molded matrices or compressed into 
tablets with very low compression force, which makes 
the tablets friable and/or brittle, difficult to handle. 
Thus it is challenging to produce ODTs that are 
sufficiently hard and durable to withstand storage, 
transportation and handling conditions 41-43 
4. Hygroscopicity:  Several orally disintegrating dosage 
forms are hygroscopic and cannot maintain physical 
integrity under normal conditions of temperature and 
humidity. Hence, they need protection from humidity 
which calls for specialized product packaging 44 
5. Amount of drug: Only limited amount of drug can be 
incorporated into a single unit of ODT. Thus it poses a 
challenge when formulating ODTs for drugs with larger 
doses. 
6. Aqueous solubility: Water-soluble drugs pose various 
formulation challenges because they form eutectic 
mixtures, which result in freezing-point depression and 
the formation of a glassy solid that may collapse upon 
drying because of loss of supporting structure during 
the sublimation process. 
7. To achieve better patient compliance, it is expected that 
no residue should remain in the mouth, after 
swallowing. 
SELECTION OF DRUGS: 
1. Drugs that produce a significant amount of toxic 
metabolites mediated by first pass liver metabolism and 
gastric metabolism can be formulated as ODT as it can 
bypass them by pre-gastric absorption 45 
2. Drugs that have a substantial fraction of absorption in 
the oral cavity and segments of the pre-gastric GIT 45 
3. Drugs having ability to diffuse and partition into the 
epithelium of the upper GIT (log P > 1, or preferable > 2) 
and those able to permeate oral mucosal tissue 46 
4. Drugs with a long half-life and less frequent dosing are 
mostly preferred 28 
5. Drugs which are very bitter or with an unacceptable 
taste are usually not preferred unless taste masking is 
possible 28 
6. Drugs which require controlled or sustained release are 
unsuitable candidates of rapidly dissolving oral dosage 
forms 28 
7. Various categories of drugs which require rapid peak 
plasma concentration like neuroleptics, cardiovascular 
agents, analgesics, anti-allergic, anti-epileptics, 
anxiolytics, sedatives, hypnotics, diuretics, anti-
parkinsonism agents, anti-bacterial agents and drugs 
used for erectile dysfunction are suitable 28 
8.  The drug must have small to moderate molecular 
weight, good solubility in water and saliva and should 
be partially unionized at oral cavity pH. 
SOME OF THE POTENTIAL DRUG CANDIDATES FOR 
ODTs: 27 
1. Analgesics and Anti-inflammatory agents: Aloxiprin, 
benorylate, difunisal, etodolac, ibuprofen etc. 
2. Anthelmintics: Albendazole, ivermectin, Dichloropen, 
cambendazole, mebendazole, etc. 
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3. Anti-Arrhythmic agents: Amiodarone HCl, 
Disopyramide, Quinidinesulphate. 
4. Anti-bacterial agents: Cinoxacin, Ciprofloxacin HCl, 
Clarithromycin, Sulphacetamide, Tetracycline, 
Trimethoprim, etc 
5. Anti-Coagulants: Dicoumarol, Dipyridamole, 
nicoumalone. 
6. Anti-depressants: Amoxapine, Ciclazindol, 
Trimipramine maleate. 
7. Anti-diabetics: Acetohexamide, Chlorpropamide, 
Glibenclamide, Tolbutamide. 
8. Anti-epileptics: Beclamide, Carbamazepine, Ethotoin, 
Methoin, Methsuximide. 
9. Anti-fungal agents: Amphotericin, 
Butoconazolenitrate, Clotrimazole, Terbinafine HCl, 
Terconazole. 
10. Anti-gout agents: Allopurinol, Probenecid, 
Sulphinpyrazone. 
11. Anti-hypertensive agents: Amlodipine, Carvedilol, 
Benidipine, Prazosin HCl, Reserpine. 
12. Anti-malarials: Amodiaquine Chloroquine, Mefloquine 
HCl, Proguanil HCl. 
13. Anti-migraine agents: Ergotamine tartarate, Pizotifen 
maleate, Sumatriptan succinate. 
14. Anti-muscarinic agents: Atropine, Benzhexol HCl, 
Biperiden, Hyoscine butyl bromide, Orphenadrine. 
15. Anti-neoplastic agents and Immunosuppressants: 
Aminoglutethimide, Amsacrine, Busulphan, Etoposide, 
Mitomycin, Mitozantrone, Testolactone. 
16. Anti-Protazoal agents: Benznidazole, Decoquinate, 
Nimotazole, Omidazole. 
17. Anti-thyroid agents: Carbimazole, Propylthiouracil. 
18. Anxiolytic, Sedatives, Hypnotics and Neuroleptics: 
Alprazolam, Amylobarbitone, carbromal, 
Chlordiazepoxide, Clobazam, Fluanisone, Haloperidol. 
19. Cardiac Inotropic agents: Amrinone, Digitoxin, 
Digoxin, Lanatoside C. 
20. Corticosteroids: Beclomethasone, Betamethasone, 
Cortosine acetate, Dexamethasone. 
 
Table 5: List of few examples of drugs available as Oro-dispersible tablets (US-FDA approved): 47 
ACTIVE INGREDIENT PROPRIETARY NAME CATEGORY STRENGHT 
Alprazolam Niravam Anti-anxiety 0.25mg, 0.5mg, 1mg, 2mg 
Amlodipine Besylate Amlodipine Besylate Anti-hypertensive Eq 2.5mg Base, Eq 5mg Base, 
Eq 10mg Base 
Aripiprazole Abilify Anti-psychotic 10mg, 15mg, 20mg, 30mg 











Central Nervous System Agents – 
Antidepressant 
Eq 10mg Base, Eq 20mg 
Base, Eq 40mg Base 
Clonazepam Klonopin Rapidly 
Disintegrating 
Antiepileptic 0.125mg, 0.25mg, 0.5mg, 
1mg, 2mg 
Clozapine Fazaclo Odt Central Nervous System Agents- 
Antipsychotics 
50mg 
Donepezil Hydrochloride Aricept Odt Central Nervous System Agents  -
Cholinesterase inhibitors 
5mg, 10mg 
Zolpidem Tartrate Tovalt Odt Central Nervous System Agents 5mg, 10mg 
 
TASTE MASKING OF DRUGS IN ODT: 
Since most of the APIs are bitter in taste, taste masking is 
very important and is the first and foremost task in the 
preparation of ODTs. A number of taste masking techniques 
are available and are listed below: 
a) Layering the drug onto inert beads using a binder and 
its subsequent coating with a taste masking polymer 48, 
49 
b) Granulating the drug and its subsequent coating with a 
taste masking polymer 49, 50 
c) Spray-drying the drug dispersed or dissolved in a 
polymeric solution to get taste-masked particles 51, 52 
d) Complexation by inclusion in cyclodextrin or drug-
resinate complex formation 53-56 
e) Co-acervation to make the drug microencapsulated 
within a polymer 57, 58 
f) Formation of pellets by extrusion spheronization or 
mass extrusion 59, 60 
TECHNOLOGIES IN THE PREPARATION OF ODT: 61 
 Freeze-Drying or Lyophilization, 
 Molding,  
 Direct Compression,  
 Disintegrant addition, 
 Sublimation,  
 Spray Drying,  
 Mass Extrusion, 
 Cotton-candy process,  
 NanoCrystal Technology, 
 Oral films/ wafers. 
 Phase transition process 
 Melt granulation. 
The orally disintegrating property of these tablets is 
attributable to the quick ingress of water into the tablet 
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matrix, which creates porous structure and results in rapid 
disintegration. Hence, the basic approaches to develop ODTs 
include maximizing the porous structure of the tablet matrix, 
incorporating the appropriate disintegrating agent and using 
highly water-soluble excipients in the formulation. 
SPECIFIC EVALUATION TESTS: 
1. Wetting time:  Wetting time of dosage form is related 
to the contact angle. It needs to be assessed to give an 
insight into the disintegration properties of the tablets; 
a lower wetting time implies a quicker disintegration of 
the tablet. For this purpose, a tablet is placed on a piece 
of tissue paper folded twice and kept in a small Petri 
dish (ID = 6.5 cm) containing 6 ml of water, and the time 
for complete wetting is measured 62 
2. Water absorption ratio: A small piece of tissue paper 
folded twice is placed in a small petridish containing 6 
ml of water. Put a tablet on the paper and the time 
required for complete wetting is measured. The wetted 
tablet is then reweighed. Water absorption ratio, R is 
determine by using following formula: 
R= 100 x Wa-Wb / Wb 
Where, Wb is the weight of tablet before water absorption, 
Wa is the weight of tablet after water absorption 22 
3. Taste/ Mouth sensation: Mouth-feel is critical, and 
patients should receive a product that feels pleasant. 
One tablet from each batch is tested for the sensation by 
placing the tablet on the tongue. The healthy human 
volunteers are used for evaluation of mouth feel. Taste 
evaluation is done by a panel of 5 members using time 
intensity method. Sample equivalent to 40 mg i.e. dose 
of drug is put in mouth for 10 seconds and record taste 
instantly and then after 10 secs, 1, 2, 4 and 6 minutes. 
Volunteer’s opinion for the taste is rated by giving 
different score values i.e. 0 = good, 1 = tasteless, 2 = 
slightly bitter, 3 = bitter, 4 = awful 22 
4. Uniformity of dispersion: Keep the Two tablets in 
100ml water and stir gently for 2 minutes. The 
dispersion is passed through 22 meshes. The tablets will 
consider passing the test if no residue remained on the 
screen 22 
5. Fineness of Dispersion: This is a qualitative test 
specified by EP for dispersible tablets. It is an 
assessment of the grittiness which arises due to 
disintegration of the tablet into coarse particles. The 
test is performed by placing two tablets in 100 ml water 
and stirring it gently, till the tablets get completely 
disintegrated. The formulation is considered to form a 
smooth dispersion if the complete dispersion passes 
through a sieve screen with a nominal mesh aperture of 
710 μm without leaving any residue on the mesh. 
6. Moisture uptake studies: Moisture uptake studies for 
ODT should be conducted to have an insight into the 
stability of the formulation, as several excipients used 
are hygroscopic. Ten tablets from each formulation are 
kept in a desiccator over calcium chloride at 370C for 24 
h. The tablets are then weighed and exposed to 75% RH 
at room temperature for two weeks. The required 
humidity (75% RH) is achieved by keeping saturated 
sodium chloride solution at the bottom of the desiccator 
for three days. One tablet as control (without 
superdisintegrant) is kept to assess the moisture uptake 
due to other excipients. Tablets are weighed and the 
percentage increase in weight is recorded 63 
7. Disintegration time: The time for disintegration of 
ODTs is generally less than one minute and actual 
disintegration time that patient can experience ranges 
from 5-30 seconds. The USP disintegration apparatus 
contains six glass tubes that are “3 long, open at the top, 
and held against 10” screen at the bottom end of the 
basket rack assembly. One tablet is placed in each tube 
and the basket rack is poisoned in 1 liter beaker of 
distilled water at 37± 2 °C, such that the tablets remain 
below the surface of the liquid on their upward 
movement and descend not closer than 2.5cm from the 
bottom of the beaker 22, 64 
8. Dissolution test:  The dissolution method for ODTs is 
identical to the approach taken for conventional tablets. 
Dissolution test was carried out on randomly selected 
from each formulation using a suitable dissolution 
apparatus. 1 mL aliquot was withdrawn at given time 
intervals and the same quantity of samples was 
immediately replaced with an equal volume of the fresh 
dissolution medium. Comparative in vitro dissolution 
study was conducted. The samples were filtered 
through membrane filters, and analyzed at suitable 
λmax in a HPLC apparatus. It has been suggested that 
USP 2 paddle apparatus is the most suitable and 
common choice for orally disintegrating tablets, with a 
paddle speed of 50 rpm commonly used 65, 66 
9. Clinical studies: In vivo studies have been performed 
on oral fast-disintegrating dosage forms to investigate 
their behavior in the oral–esophageal tract, their 
pharmacokinetic and therapeutic efficacy, and 
acceptability. Its dissolution and buccal clearance was 
rapid 67; the esophageal transit time and stomach 
emptying time were comparable with those of 
traditional tablets, capsules, or liquid forms. A 
decreased inter subject variability in transit time was 
also observed. 68, 69. It also showed good therapeutic 
efficacy and patient acceptability - particularly in 
children, 70, 71 or when easy administration and rapid 
onset of action were required (such as for patients 
undergoing surgery). 72, 73) The fast disintegrating forms 
examined showed improved pharmacokinetic 
characteristics when compared with reference oral solid 
formulations. All the drugs that can be absorbed 
through the buccal and esophageal mucosa exhibited 
increased bioavailability and side-effect reduction. This 
is helpful particularly in actives with marked first-pass 
hepatic metabolism 74 
10. Stability studies:  ODT formulations were packed in 
aluminum foil and exposed to 25 ± 2°C/60 ± 5% relative 
humidity (RH) and 40 ± 2°C/75 ± 5%RH in stability 
chambers for 3 months. At pre-set time intervals 
evaluation of drug content in each tablet was performed 
29 
11. Statistical analysis: The resulting data were analyzed 
by using SPSS 17.0 software (SPSS Inc.,Chicago, USA) 
applying non-parametric methods. The limit of 
significance was set at p < 0.05 29 
FUTURE OF ODT 
Industry observers point to broadening use of ODT 
technology. These include the incorporation of 
macromolecules using ODT into vaccines. Other areas 
include: the incorporation of encapsulated APIs to achieve 
modified-release profiles within the convenience of an ODT; 
and the further development of superdisintegrants for 
incorporation into conventional, compressed tablets, 
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potentially widening the opportunity for ODT development 
to non-specialist companies 30 
Another emerging area is the wider application of ‘oral thin-
strip technologies’. Thin-film strip technology uses a range of 
water-soluble polymers and is reported to be able to 
incorporate water soluble, insoluble, or taste-masked 
ingredients. The film is manufactured as a continuous sheet 
and then cut into individual doses prior to packing. The 
major limitations to this technology are the relatively low 
doses that can be accommodated (approximately 30 mg) and 
its moisture sensitivity thus requiring specific unit-dose 
packaging to protect the product and ensure shelf life 75 
Should next generation drugs be predominantly protein or 
peptide based, tablets may no longer be the dominant format 
for dosing such moieties, as ODTs may be more suitable for 
the oral delivery of these drugs that have limited 
bioavailability when administered by conventional tablets 30 
FDC-ODT 
There is an ocean of advantage in both FDC products and 
ODT products. Thus the incorporation of two or more fixed 
dose combination of drugs into oro-dispersible tablets will 
have a combined advantage of better compliance and efficacy 
especially to dysphagic patients. 
Definition: “A FDC ODT formulation has a combination of 
two or more drugs based on scientific and medical rationale 
in an oro-dispersible tablet form which produces synergistic 
effect used in treatment of one or even more ailments”. This 
FDC ODT formulation is also expected to give immediate 
disintegration and therefore rapid drug release thus 
increasing patient compliance due to their convenience as a 
dosage form. 
Bringing together the techniques of FDC and ODT is 
desirable because in some cases the disadvantage of one 
technique can be overcome by the other. For instance, a 
major disadvantage of the FDC formulations is its size. 
Combining two or more actives will result in a bigger size of 
the tablet. But once it is formulated as ODT, the size will not 
be problem as it will disintegrate in the mouth and there will 
not be any swallowing issue. 
For a successful development of a FDC ODT formulation, 
bioequivalence comparison between the single and FDC 
formulations, using in vitro dissolution and Caco-2 apparent 
permeability (Papp) and in silico physiologically based 
pharmacokinetic modeling approaches should be carried 
out. Once we come to know that there is no change in 
bioavailability for FDCs when compared with individual 
products, we can be sure that the FDC ODT formulations will 
also be bioequivalent owing to their immediate 
disintegration and therefore rapid drug release 10 
FIXED DOSE COMBINATION OF DRUGS HAVING 
SCOPE TO BE GIVEN AS ODT PRODUCTS 
Research has been carried out using the following 
combination of drugs  
1. Amlodipine + Ramipril 76 
2. Amlodipine + Atorvastatin 77 
3. Ambroxol Hydrochloride + Salbutamol Sulphate 78 
4. Prifinium Bromide + Diclofenac Sodium 79 
5. Ambroxol Hydrochloride + Cetrizine Hydrochloride 80 
6. Lopinavir + Ritonavir 81 
7. Hydrochlorothiazide + Amlodipine besylate 82 
8. Montelukast + Fexofenadine 
CONCLUSION 
The FDC-ODT products have potential advantages over 
conventional oral dosage forms as they improved patient 
compliance; convenience, rapid onset of action and 
bioavailability which drawn the attention of many 
manufactures. The patient populations which will be 
primarily benefited by the FDC-ODT products will be the 
pediatric and geriatric populations as they will be more 
prone to swallowing problems and for whom the frequency 
of dosing has to be reduced. Also these products help to 
achieve rapid disintegration and instantaneous dissolution of 
the tablet along with good taste masking properties and 
excellent mechanical strength. Many drugs can be 
incorporated in FDC-ODT products, especially unpalatable 
drugs. In spite of the many advantages it possesses, rarely do 
the FDC-ODT products come to commercial market. Further 
research must be carried out properly and more products 
need to be commercialized to use this technology properly.  
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